Google Life Sciences and Sanofi collaborate in fight against diabetes

A new partnership has been formed between Sanofi and Google to develop new methods of monitoring and treating diabetes.
Sanofi, the French pharmaceutical company that is known for its medical products such as Lantus (insulin glargine) and Lyxumia (lixisenatide), will provide expertise on diabetes treatment.
Google’s Life Sciences division, which is working on how devices can continuously collect diabetes-related data, will be researching how technology can benefit diabetes management.
The mutual aim is for people with diabetes to receive information such as blood glucose levels, HbA1c and medication regimens through new technology. As a result, diabetes management will improve and the risk of diabetes-related complications will decrease.
In a separate venture, Google Life Sciences recently paired up with DexCom to develop a new generation of smaller continuous glucose monitors (CGMs). According to Andrew Conrad, CEO of Google Life Sciences, the Sanofi partnership will enable new kinds of interventions regarding diabetes treatment.
“With Sanofi, we can complete the picture of how diabetes unfolds and try to interrupt that development through a proactive and preventive approach,” said Conrad.
This new collaboration is the latest in a number of recent worldwide partnerships between pharmaceutical and technology companies in the fight against diabetes.
Google Life Sciences have also partnered up with Novartis to develop a contact lens that can monitor blood glucose levels, while Sanofi announced in August that they were working with Evotec to remove the need for patients to inject insulin.